Seven people in Victoria, Australia, have now been hospitalised with acute liver toxicity after using an unapproved peptide sold as retatrutide, according to ABC News Australia. Doctors are testing products associated with the cases while investigating whether a contaminated counterfeit batch may be responsible. The suspected batch connection has not been confirmed by laboratory results.
The latest patient became seriously unwell after a second dose of an unregulated product labelled retatrutide. Liver-transplant specialist Marie Sinclair told ABC that affected patients developed severe liver injury within weeks of using the black-market product. Reported symptoms included jaundice and worsening liver function. The clustering of cases in Victoria has prompted concern about a localised supply problem, although the cause remains under investigation.
This is not evidence about clinical-trial retatrutide
The product involved in these hospitalisations is not pharmaceutical-grade retatrutide supplied through Eli Lilly’s clinical trials. Robyn Langham, chief medical adviser at Australia’s Therapeutic Goods Administration (TGA), described online retatrutide as counterfeit, unapproved, and untested, and said the product being sold is not the retatrutide currently in clinical trials. Canberra Health Services has also confirmed liver injuries associated with products sold as retatrutide, without disclosing a case count.
That distinction matters. A vial bought online may contain the wrong substance, an incorrect concentration, contaminants, or no retatrutide at all. These reports cannot establish that retatrutide itself caused the injuries, and they should not be treated as a clinical-trial safety signal. They do show the danger of injecting an unverified product outside a regulated supply chain.
The TGA has warned that unapproved peptide products can cause serious harm and reported that Australian authorities destroyed more than 94,500 units of unapproved peptide products during 2026. Anyone who has used an unregulated injectable and develops jaundice, dark urine, unusual fatigue, abdominal pain, persistent nausea, or other concerning symptoms should seek urgent medical care and tell clinicians exactly what was taken.
What Canadians should take from the warning
Retatrutide is not approved by Health Canada and is not legally available for routine sale in Canada. Canadian consumers ordering from overseas websites, social-media sellers, or messaging groups face the same basic hazard: the label does not prove the contents, sterility, dose, or manufacturing quality. Health Canada warns against buying health products from unauthorized online sources, where products may be counterfeit or contaminated.
Legitimate Canadian access remains limited to participation in an authorized clinical trial or, in appropriate circumstances, a physician-led request through Health Canada’s Special Access Programme. Neither pathway involves buying a vial from an online peptide vendor. Canadians who suspect an unsafe health product should report it through Health Canada’s adverse reaction reporting service and should not continue using a product associated with illness without medical advice.
Sources
- ABC News Australia: Doctors fear possible contaminated counterfeit peptide batch after seventh case of acute liver damage (August 24, 2026)
- UA.NEWS: Seven people hospitalised in Victoria after using counterfeit retatrutide (August 24, 2026)
- Health Canada: Special Access Programme — Drugs
- Health Canada: Health product safety alerts